Literature DB >> 17465839

Transplantation of human embryonic stem cell-derived oligodendrocyte progenitors into rat spinal cord injuries does not cause harm.

Frank Cloutier1, Monica M Siegenthaler, Gabriel Nistor, Hans S Keirstead.   

Abstract

Demyelination contributes to loss of function following spinal cord injury. We have shown previously that transplantation of human embryonic stem cell-derived oligodendrocyte progenitors into adult rat 200 kD contusive spinal cord injury sites enhances remyelination and promotes recovery of motor function. Previous studies using oligodendrocyte lineage cells have noted a correlation between the presence of demyelinating pathology and the survival and migration rate of the transplanted cells. The present study compared the survival and migration of human embryonic stem cell-derived oligodendrocyte progenitors injected 7 days after a 200 or 50 kD contusive spinal cord injury, as well as the locomotor outcome of transplantation. Our findings indicate that a 200 kD spinal cord injury induces extensive demyelination, whereas a 50 kD spinal cord injury induces no detectable demyelination. Cells transplanted into the 200 kD injury group survived, migrated, and resulted in robust remyelination, replicating our previous studies. In contrast, cells transplanted into the 50 kD injury group survived, exhibited limited migration, and failed to induce remyelination as demyelination in this injury group was absent. Animals that received a 50 kD injury displayed only a transient decline in locomotor function as a result of the injury. Importantly, human embryonic stem cell-derived oligodendrocyte progenitor transplants into the 50 kD injury group did not cause a further decline in locomotion. Our studies highlight the importance of a demyelinating pathology as a prerequisite for the function of transplanted myelinogenic cells. In addition, our results indicate that transplantation of human embryonic stem cell-derived oligodendrocyte progenitor cells into the injured spinal cord is not associated with a decline in locomotor function.

Entities:  

Mesh:

Year:  2006        PMID: 17465839     DOI: 10.2217/17460751.1.4.469

Source DB:  PubMed          Journal:  Regen Med        ISSN: 1746-0751            Impact factor:   3.806


  38 in total

Review 1.  Pluripotent Stem Cells and Other Innovative Strategies for the Treatment of Ocular Surface Diseases.

Authors:  Johanna Erbani; Daniel Aberdam; Jerome Larghero; Valérie Vanneaux
Journal:  Stem Cell Rev Rep       Date:  2016-04       Impact factor: 5.739

2.  Developing safe therapies from human pluripotent stem cells.

Authors:  Melissa K Carpenter; Joyce Frey-Vasconcells; Mahendra S Rao
Journal:  Nat Biotechnol       Date:  2009-07       Impact factor: 54.908

3.  Achieving stable human stem cell engraftment and survival in the CNS: is the future of regenerative medicine immunodeficient?

Authors:  Aileen J Anderson; Daniel L Haus; Mitra J Hooshmand; Harvey Perez; Christopher J Sontag; Brian J Cummings
Journal:  Regen Med       Date:  2011-05       Impact factor: 3.806

Review 4.  Improving the therapeutic efficacy of neural progenitor cell transplantation following spinal cord injury.

Authors:  Michael A Lane; Angelo C Lepore; Itzhak Fischer
Journal:  Expert Rev Neurother       Date:  2016-12-21       Impact factor: 4.618

Review 5.  A systematic review of cellular transplantation therapies for spinal cord injury.

Authors:  Wolfram Tetzlaff; Elena B Okon; Soheila Karimi-Abdolrezaee; Caitlin E Hill; Joseph S Sparling; Jason R Plemel; Ward T Plunet; Eve C Tsai; Darryl Baptiste; Laura J Smithson; Michael D Kawaja; Michael G Fehlings; Brian K Kwon
Journal:  J Neurotrauma       Date:  2010-04-20       Impact factor: 5.269

Review 6.  Stem cells in human neurodegenerative disorders--time for clinical translation?

Authors:  Olle Lindvall; Zaal Kokaia
Journal:  J Clin Invest       Date:  2010-01       Impact factor: 14.808

7.  Histological and functional benefit following transplantation of motor neuron progenitors to the injured rat spinal cord.

Authors:  Sharyn L Rossi; Gabriel Nistor; Tanya Wyatt; Hong Zhen Yin; Aleksandra J Poole; John H Weiss; Matthew J Gardener; Sipke Dijkstra; David F Fischer; Hans S Keirstead
Journal:  PLoS One       Date:  2010-07-29       Impact factor: 3.240

8.  MHC mismatch results in neural progenitor cell rejection following spinal cord transplantation in a model of viral-induced demyelination.

Authors:  Jason G Weinger; Brian M Weist; Warren C Plaisted; Suzi M Klaus; Craig M Walsh; Thomas E Lane
Journal:  Stem Cells       Date:  2012-11       Impact factor: 6.277

Review 9.  Cell therapy for spinal cord regeneration.

Authors:  Stephanie M Willerth; Shelly E Sakiyama-Elbert
Journal:  Adv Drug Deliv Rev       Date:  2007-10-05       Impact factor: 15.470

Review 10.  Development of biomaterial scaffold for nerve tissue engineering: Biomaterial mediated neural regeneration.

Authors:  Anuradha Subramanian; Uma Maheswari Krishnan; Swaminathan Sethuraman
Journal:  J Biomed Sci       Date:  2009-11-25       Impact factor: 8.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.